Association of the BH3 mimetic ABT-199 (Venetoclax), a more specific BCL-2 inhibitor, with either Imatinib [26] or Nilotinib [27] synergistically induced death of quiescent stem/progenitor primary CML CD34+ cells. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.